Takeda Pharmaceutical Co. has increased its projected operating income for the fiscal year ending March 2025 by 18% to ¥265 billion ($1.7 billion) due to a strong second-quarter performance.
This adjustment is a result of the company's successful sales of key drugs and cost-saving measures in North America. Previously, the forecast for operating income was ¥225 billion.
These positive changes reflect Takeda's ongoing efforts to restructure and improve operational efficiency.